AML and MDS resources and support for patients

Patient Resources

Resources for practices that guide patients

Patient and Caregiver Brochure

Download this brochure featuring dosing guidance, side effect management, and financial support.

Patient and Caregiver Brochure

Co-Pay Brochure

Download this brochure featuring eligibility criteria and enrollment details for the Taiho Oncology Co-Pay Assistance Program.

Co-Pay Brochure

Enrollment Form

Download and print this form, and fax the completed form to 1‑844‑287‑2559.

Enrollment Form (English) Enrollment Form (Spanish)

Taiho Oncology Patient Support™ for you and your patients

Taiho Oncology Patient Support offers personalized services to help patients, caregivers, and healthcare professionals access Taiho Oncology products. This includes insurance coverage determination and help with medication affordability. For more information, please visit or refer patients to TaihoPatientSupport.com.

Eligible, commercially insured patients can enroll in the Taiho Oncology Patient Support Co‑Pay Program, which may help reduce out-of-pocket expenses to $0* for their treatment with INQOVI. To determine patient eligibility, visit TaihoOncologyCoPay.com or call 1‑844‑TAIHO‑4U (1‑844‑824‑4648).

Taiho Oncology Patient Support can assist with:

Insurance coverage support

Benefits investigation
Prior authorization assistance
Appeals assistance
Coordination of prescriptions with pharmacies

Patient affordability assistance^†

$0 Co-Pay Program enrollment for eligible commercially insured patients
Patient assistance program designed to provide free medication to eligible patients who are uninsured or underinsured
Referrals to third-party foundations for co-pay or other assistance based on eligibility and additional criteria
Referrals to Medicare Part D Low-Income Subsidy (LIS)/Extra Help Program

Personalized nurse support^‡

One-on-one nurse educational support for patients, available via opt-in

Enroll in Taiho Oncology Patient Support:

By fax

Download the Enrollment Form, print it out to complete, and fax the completed form to 1-844-287-2559.

Enrollment Form (English)

Enrollment Form (Spanish)

By phone

Call 1-844-TAIHO-4U (1-844-824-4648) for help with enrollment.

*Restrictions and eligibility: Offer valid in the US, Puerto Rico, and US territories only. Only valid for patients with private insurance. Offer not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefit plan, Tricare, or other federal or state programs (such as medical assistance programs). If the patient is eligible for drug benefits under any such program, this offer is not valid and the patient cannot use this offer. By presenting or accepting this benefit, patient and pharmacist agree not to submit claim for reimbursement under the above programs. Patient further agrees to comply with any and all terms of his or her health insurance contract requiring notification to his or her payer of the existence and/or value of this offer. It is illegal to or offer to sell, purchase, or trade this benefit. Maximum reimbursement limits apply; patient out-of-pocket expense may vary. Taiho Oncology, Inc., reserves the right to rescind, revoke, or amend this offer at any time without notice.

^†Visit TaihoPatientSupport.com to see full eligibility criteria.

^‡If this option is selected on the Patient Enrollment Form, a Nurse Navigator will be assigned to provide telephone support and will address general inquiries about INQOVI, your patient's Taiho Oncology medicine treatment.

Patient advocacy organizations

American Cancer Society (ACS)

24/7 support line, disease education, transportation to treatment, and lodging assistance

1-800-227-2345 | cancer.org

Aplastic Anemia and MDS International Foundation (AAMDSIF)

Educational materials, one-on-one support, clinical trial listings, and local events for patients with MDS

1-800-747-2820 | aamds.org

Blood Cancer United

Personalized support, financial aid, clinical trial navigation, and disease-specific information

1-800-955-4572 | bloodcancerunited.org

CancerCare

Free counseling, support groups, financial assistance, and educational resources for patients with AML or MDS and their caregivers

1-800-813-4673 | cancercare.org

HealthTree Foundation

Education, clinical trial matching, expert directories, and community support for patients with AML or MDS and their caregivers

1-800-709-1113 | healthtree.org

Know AML

Global awareness initiative offering educational tools and support for patients with AML and their caregivers

know-aml.com

Leukemia Research Foundation (LRF)

Patient education, financial support, and research funding focused on advancing leukemia care

1-847-424-0600 | leukemiarf.org

The Max Foundation

Access to treatment, emotional support, and care navigation for patients with AML in underserved regions

1-425-778-8660 | themaxfoundation.org

Myelodysplastic Syndromes (MDS) Foundation

Trusted MDS information, insurance navigation, treatment center referrals, and events for patients with MDS and their caregivers

1-800-637-0839 | mds-foundation.org

Additional resources
youandmds.com
youandaml.com

These organizations are independent and not affiliated with Taiho Oncology. This list is provided for informational purposes only.

Practice resources

Practices may find these resources helpful when prescribing INQOVI.

Explore practice resources

Request a representative

A Taiho rep will reach out if you are interested in additional resources.

Request a rep

INDICATIONS AND IMPORTANT SAFETY INFORMATION

INDICATIONS

INQOVI is indicated for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.

INQOVI is indicated in combination with venetoclax for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Myelosuppression
INQOVI as Monotherapy for MDS or CMML
In patients with MDS or CMML, INQOVI can cause severe myelosuppression, including fatal adverse reactions. Based on laboratory values, new or worsening thrombocytopenia occurred in 82% of patients, with Grade 3 or 4 occurring in 76%. Neutropenia occurred in 73% of patients, with Grade 3 or 4 occurring in 71%. Anemia occurred in 71% of patients, with Grade 3 or 4 occurring in 55%. Febrile neutropenia occurred in 33% of patients, with Grade 3 or 4 occurring in 32%. Thrombocytopenia, neutropenia, anemia, and febrile neutropenia are the most frequent cause of INQOVI dose reduction or interruption, occurring in 36% of patients. Permanent discontinuation due to myelosuppression (febrile neutropenia) occurred in 1% of patients. Myelosuppression and worsening neutropenia may occur more frequently in the first or second treatment cycles and may not necessarily indicate progression of underlying MDS.

Fatal and serious infectious complications can occur with INQOVI. Pneumonia occurred in 21% of patients, with Grade 3 or 4 occurring in 15%. Sepsis occurred in 14% of patients, with Grade 3 or 4 occurring in 11%. Fatal pneumonia occurred in 1% of patients, fatal sepsis in 1%, and fatal septic shock in 1%.

Obtain complete blood cell counts prior to initiation of INQOVI, prior to each cycle, and as clinically indicated to monitor response and toxicity. Administer growth factors and anti‑infective therapies for treatment or prophylaxis as appropriate. Delay the next cycle and resume at the same or reduced dose as recommended.

INQOVI in Combination with Venetoclax for AML
In patients with AML, INQOVI can cause severe myelosuppression, including fatal adverse reactions, when given in combination with venetoclax. Based on laboratory values in Study ASTX727-07, Phase 2 new or worsening thrombocytopenia occurred in 70% of patients, with Grade 3 or 4 occurring in 69%. Neutropenia occurred in 48% of patients, with Grade 3 or 4 occurring in 48%. Anemia occurred in 54% of patients, with Grade 3 or 4 occurring in 50%. Febrile neutropenia occurred in 52% of patients, with Grade 3 or 4 occurring in 52%. Thrombocytopenia, neutropenia, anemia, and febrile neutropenia were a frequent cause of INQOVI and/or venetoclax dose reduction or interruption. Dose reductions of INQOVI due to neutropenia and thrombocytopenia occurred in 4% and 1% of patients, respectively. Dose interruptions of INQOVI due to neutropenia, febrile neutropenia, thrombocytopenia, and anemia occurred in 40%, 11%, 8%, and 2% of patients, respectively.

Fatal and serious infectious complications can occur during treatment with INQOVI and venetoclax. Pneumonia occurred in 25% of patients, with Grade 3 or 4 occurring in 20%. Sepsis occurred in 28% of patients, with Grade 3 or 4 occurring in 18%. Fatal pneumonia occurred in 2% of patients and fatal sepsis in 8%.

Obtain complete blood cell counts prior to initiation of INQOVI with venetoclax, prior to each cycle, and as clinically indicated to monitor response and toxicity. Administer growth factors and anti-infective therapies for treatment or prophylaxis as appropriate. Delay the next cycle and resume at the same or reduced dose as recommended.

Embryo-Fetal Toxicity
Advise patients of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with INQOVI and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with INQOVI and for 3 months after the last dose.

ADVERSE REACTIONS

INQOVI as Monotherapy for MDS or CMML
Serious adverse reactions occurred in 68% of patients who received INQOVI. Serious adverse reactions in >5% of patients included febrile neutropenia (30%), pneumonia (14%), and sepsis (13%). Fatal adverse reactions occurred in 6% of patients. These included sepsis (1%), septic shock (1%), pneumonia (1%), respiratory failure (1%), and one case each of cerebral hemorrhage and sudden death.

The most common adverse reactions (≥20%) were fatigue (55%), constipation (44%), hemorrhage (43%), myalgia (42%), mucositis (41%), arthralgia (40%), nausea (40%), dyspnea (38%), diarrhea (37%), rash (33%), dizziness (33%), febrile neutropenia (33%), edema (30%), headache (30%), cough (28%), decreased appetite (24%), upper respiratory tract infection (23%), pneumonia (21%), and transaminase increased (21%). The most common Grade 3 or 4 laboratory abnormalities (≥50%) were leukocytes decreased (81%), platelet count decreased (76%), neutrophil count decreased (71%), and hemoglobin decreased (55%).

INQOVI in Combination with Venetoclax for AML
Serious adverse reactions occurred in 82% of patients who received INQOVI+VEN. Serious adverse reactions in >5% of patients included febrile neutropenia (31%), sepsis (22%), pneumonia (15%), infection (bacterial/viral) (10%), hemorrhage (9%), and dyspnea (6%). Fatal adverse reactions occurred in 8% of patients who received INQOVI+VEN. These included sepsis (5%), dyspnea (2%), myocardial infarction (1%), hemolytic anemia (1%), and tumor lysis syndrome (1%).

The most common adverse reactions (≥20%) were neutropenia (60%), febrile neutropenia (52%), thrombocytopenia (52%), hemorrhage (42%), anemia (41%), infection (bacterial/viral) (40%), diarrhea (38%), fatigue (36%), mucositis (36%), constipation (36%), arthralgia (35%), decreased appetite (31%), edema (31%), nausea (31%), dyspnea (30%), white blood cell count decreased (28%), sepsis (28%), pneumonia (25%), rash (25%), transaminitis (24%), myalgia (23%), arrhythmia (21%), and abdominal pain (21%). The most common Grade 3 or 4 laboratory abnormalities (≥20%) were decreased leukocytes (91%), decreased lymphocytes (81%), decreased platelets (69%), decreased hemoglobin (50%), and decreased neutrophils (48%).

USE IN SPECIFIC POPULATIONS

Lactation
Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with INQOVI and for 2 weeks after the last dose.

Renal Impairment
No dosage modification of INQOVI is recommended for patients with mild or moderate renal impairment (creatinine clearance [CLcr] of 30 to 89 mL/min based on Cockcroft-Gault). Due to the potential for increased adverse reactions, monitor patients with moderate renal impairment (CLcr 30 to 59 mL/min) frequently for adverse reactions. INQOVI has not been studied in patients with severe renal impairment (CLcr 15 to 29 mL/min) or end-stage renal disease (ESRD: CLcr <15 mL/min).

Please see full Prescribing Information.

AML and MDS resources and support for patients

Resources for practices that guide patients

Patient and Caregiver Brochure

Co-Pay Brochure

Enrollment Form

Taiho Oncology Patient Support™ for you and your patients

Taiho Oncology Patient Support can assist with:

Insurance coverage support

Patient affordability assistance^†

Personalized nurse support^‡

Enroll in Taiho Oncology Patient Support:

By fax

By phone

Patient advocacy organizations

American Cancer Society (ACS)

Aplastic Anemia and MDS International Foundation (AAMDSIF)

Blood Cancer United

CancerCare

HealthTree Foundation

Know AML

Leukemia Research Foundation (LRF)

The Max Foundation

Myelodysplastic Syndromes (MDS) Foundation

Practice resources

Request a representative

INDICATIONS AND IMPORTANT SAFETY INFORMATION

INDICATIONS

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

USE IN SPECIFIC POPULATIONS

Choose when your patient will start INQOVI + venetoclax for AML

Print the calendar to help your patient get started

Choose when your patient will start INQOVI for MDS

Print the calendar to help your patient get started

AML and MDS resources and support for patients

Resources for practices that guide patients

Patient and Caregiver Brochure

Co-Pay Brochure

Enrollment Form

Taiho Oncology Patient Support™ for you and your patients

Taiho Oncology Patient Support can assist with:

Insurance coverage support

Patient affordability assistance†

Personalized nurse support‡

Enroll in Taiho Oncology Patient Support:

By fax

By phone

Patient advocacy organizations

American Cancer Society (ACS)

Aplastic Anemia and MDS International Foundation (AAMDSIF)

Blood Cancer United

CancerCare

HealthTree Foundation

Know AML

Leukemia Research Foundation (LRF)

The Max Foundation

Myelodysplastic Syndromes (MDS) Foundation

Practice resources

Request a representative

INDICATIONS AND IMPORTANT SAFETY INFORMATION

INDICATIONS

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

USE IN SPECIFIC POPULATIONS

Choose when your patient will start INQOVI + venetoclax for AML

Print the calendar to help your patient get started

Choose when your patient will start INQOVI for MDS

Print the calendar to help your patient get started

Patient affordability assistance^†

Personalized nurse support^‡